Seven Eight Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Seven Eight Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,750	Closed	-$623K	–	690
2023 Q1	$623K	Sell	16,750 -26,514	-61%	-$1.19M	0.13%	208
2022 Q4	$1.96M	Buy	+43,264	New	+$2.8M	0.51%	54
2021 Q2	–	Sell	-1,686	Closed	-$370K	–	742
2021 Q1	$370K	Hold	1,686	–	–	0.09%	304
2020 Q4	$370K	Buy	1,686 +400	+31%	+$86.5K	0.08%	307
2020 Q3	$214K	Buy	+1,286	New	+$176K	0.05%	511
2019 Q3	–	Sell	-29,291	Closed	-$3.02M	–	761
2019 Q2	$3.02M	Buy	+29,291	New	+$2.28M	0.16%	192

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Seven Eight Capital's MRTX Position: Q2 2023 in Review

Seven Eight Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 16,750 shares — an estimated $623K sold.

Seven Eight Capital first reported a position in MRTX in Q2 2019 and held it in 6 quarters. The position peaked at $3.02M in Q2 2019. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Seven Eight Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Seven Eight Capital sold 16,750 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $623K.
Seven Eight Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Seven Eight Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $3.02M in Q2 2019.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Seven Eight Capital's 13F filing for Q2 2023, filed 14 Aug 2023.